



## Original Contribution

## Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models

Ping Chen <sup>a,b,c</sup>, Jennifer Stone <sup>a</sup>, Garrett Sullivan <sup>a</sup>, Jeanne A. Drisko <sup>a</sup>, Qi Chen <sup>a,b,\*</sup><sup>a</sup> Program in Integrative Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA<sup>b</sup> Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA<sup>c</sup> Department of Genetic and Molecular Biology, Xi'an Jiaotong University School of Medicine, Xi'an 710061, China

## ARTICLE INFO

## Article history:

Received 7 January 2011

Revised 20 May 2011

Accepted 23 May 2011

Available online xxxx

## Keywords:

Ascorbic acid (ascorbate)

Vitamin C

Glutathione

Cancer

Hydrogen peroxide

Free radicals

## ABSTRACT

Two popular complementary, alternative, and integrative medicine therapies, high-dose intravenous ascorbic acid (AA) and intravenous glutathione (GSH), are often coadministered to cancer patients with unclear efficacy and drug–drug interaction. In this study we provide the first survey evidence for clinical use of iv GSH with iv AA. To address questions of efficacy and drug–drug interaction, we tested 10 cancer cell lines with AA, GSH, and their combination. The results showed that pharmacologic AA induced cytotoxicity in all tested cancer cells, with IC<sub>50</sub> less than 4 mM, a concentration easily achievable in humans. GSH reduced cytotoxicity by 10–95% by attenuating AA-induced H<sub>2</sub>O<sub>2</sub> production. Treatment in mouse pancreatic cancer xenografts showed that intraperitoneal AA at 4 g/kg daily reduced tumor volume by 42%. Addition of intraperitoneal GSH inhibited the AA-induced tumor volume reduction. Although all treatments (AA, GSH, and AA + GSH) improved survival rate, AA + GSH inhibited the cytotoxic effect of AA alone and failed to provide further survival benefit. These data confirm the pro-oxidative anti-cancer mechanism of pharmacologic AA and suggest that AA and GSH administered together provide no additional benefit compared with AA alone. There is an antagonism between ascorbate and glutathione in treating cancer, and therefore iv AA and iv GSH should not be coadministered to cancer patients on the same day.

© 2011 Elsevier Inc. All rights reserved.

Intravenous (iv) vitamin C or ascorbic acid (AA) has been used in cancer treatment for many years [1–8]. Until recently the extent of iv AA use in complementary, alternative, and integrative medicine (CAIM) practices was unknown [9]. From the reported survey data, it is now known that iv AA is in wide use and doses up to 200 g per infusion are used to treat a variety of conditions, including cancer. Intravenous AA infusions are remarkably safe, with very few adverse events reported in approximately 20,000 patients in 2 years' time.

Intravenous AA has a very different mechanism of action compared to its oral use [10]. Mechanistic studies show that intravenous, but not oral, AA produces pharmacologic plasma concentrations that result in the production of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in the extracellular space [11–13] and then result in neoplastic cytotoxicity [12–15]. These plasma concentrations of ascorbate are attainable in human clinical trials [12,16]. Taken as a whole, iv AA is a prodrug

for H<sub>2</sub>O<sub>2</sub> production in the extracellular space, resulting in targeted neoplastic cell death, and as such is a pro-oxidative therapy.

Intravenous glutathione (GSH) is another CAIM therapy known anecdotally to be in wide use. Unfortunately the extent and pattern of iv GSH use by survey, unlike iv AA, have never been determined. There are animal studies, case reports, and small clinical trials using supraphysiologic doses of parenteral GSH in a variety of disorders, including cancer, but none addressed the actual numbers of infusions of GSH given to patients each year [17–24].

GSH is a tripeptide of glutamate, cysteine, and glycine that actively scavenges reactive oxygen species such as superoxide, hydroxyl radical, and notably, H<sub>2</sub>O<sub>2</sub> [25–29]. GSH has been shown to work synergistically with AA to remove and quench reactive oxygen species at physiologic concentrations of AA (<200 μM) that are often achieved with oral supplementation [30–32]. However, at supraphysiologic concentrations obtained by iv administration, at which AA acts as a pro-oxidant inducing the production of H<sub>2</sub>O<sub>2</sub>, the synergistic relationship may not hold true. In fact if GSH's role is to clear H<sub>2</sub>O<sub>2</sub>, the therapeutic benefit of iv AA may be nullified by coadministration of iv GSH.

Anecdotal evidence shows that CAIM practitioners are concurrently administering iv AA with iv GSH during the same clinic visit, but the extent and frequency are not known. To assess the actual use of iv GSH and the concomitant use of iv GSH and iv AA in patients, we

*Abbreviations:* AA or AsCh, ascorbic acid or ascorbate; Asc<sup>•</sup>, ascorbate radical; CAIM, complementary, alternative, and integrative medicine; DHA, dehydroascorbic acid; GSH, glutathione; IC<sub>50</sub>, 50% inhibition concentration; ip, intraperitoneal; iv, intravenous; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; O<sub>2</sub><sup>•-</sup>, superoxide radical; ROS, reactive oxygen species.

\* Corresponding author at: Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA. Fax: +1 913 945 6751.

E-mail address: [qchen@kumc.edu](mailto:qchen@kumc.edu) (Q. Chen).

conducted a survey among CAIM practitioners. As the plausibility of AA as a cancer treatment increases and mounting research ties this to AA's pro-oxidant activity, it is imperative to study whether the combination of GSH as an antioxidant benefits or antagonizes the AA effect. Here we investigate the effect in cancer cell lines and in an animal model when combining the two treatments. We hypothesize that there may be interference in the antineoplastic effect by increased clearance of H<sub>2</sub>O<sub>2</sub> when iv AA is administered concurrent with iv GSH.

## Methods

### Survey methods

The study was reviewed by the Human Subjects Committee/Institutional Review Board at the University of Kansas Medical Center and categorized as an exempt study. Survey forms were distributed to practitioners attending an annual CAIM conference in April 2011. Surveys were distributed and collected on 3 successive days. Participants were asked whether they administer high-dose iv vitamin C or iv GSH and, if they use both, whether they administer the two agents concurrently in the same patient. Participants were also asked to detail the use of iv GSH by answering specific questions about dosing amounts and frequency of dosing (see Survey S1 for the survey form used).

### Cells and reagents

Human lung cancer cell line A549, breast cancer cell line MCF-7, and melanoma cell line B16 were purchased from the American Type Culture Collection (Manassas, VA, USA). Human pancreatic cancer cell line HPAF-II was kindly donated by Dr. R. Puri, FDA/CBER (Bethesda, MD, USA), MIA PaCa-2 by Dr. J. Cullen, University of Iowa (Iowa City, IA, USA), PANC-1 by Dr. M. Brownstein, J. Craig Venter Institute (Rockville, MD, USA), murine pancreatic cancer line PAN-02 by Dr. A. Sandler, Children's Hospital Medical Center (Washington, DC, USA), human ovarian cancer cell line OvCar5 by Dr. P. Eck, NIDDK/NIH (Bethesda, MD, USA), and prostate cancer cell line PC-3 by Dr. B. Li, University of Kansas Medical Center (Kansas City, KS, USA). A human cervical cancer cell line transfected with the fluorescent hydrogen peroxide sensor HyPer (HeLa-HyPer-Cyto) was donated by Dr. M. Levine, NIDDK/NIH, and cells were maintained in DMEM supplemented with 10% fetal bovine serum and 100 µg/ml G418. Cell lines were independently authenticated where applicable (RADIL, Columbia, MO, USA). Glutathione injectables were purchased from Wellness Pharmacy (Birmingham, AL, USA) and stored at 4 °C. Ascorbate (Sigma, St. Louis, MO, USA) was prepared as 1 M stock solutions in sterile water, with sodium hydroxide added drop-wise to adjust the pH to 7.0. Aliquots stored frozen at –80 °C were thawed for single use.

### Cell viability assay

Cells (1 × 10<sup>4</sup>) in exponential growth phase were cultured at 37 °C in 5% CO<sub>2</sub>/95% air in the recommended growth medium containing 10% fetal bovine serum and exposed to serial dilutions of AA and/or GSH for 48 h. Because of oxidation and ascorbate disappearance over the incubation time, the actual exposure time is relevant to clinical iv AA use, in which pharmacological AA concentrations typically persist for 6–8 h [9,12,16]. Before being assessed for relative proliferation, cells were washed with PBS and changed into fresh medium. Relative viability was detected by colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, based on the ability of living, but not dead, cells to reduce MTT to formazan [33,34]. Half-inhibitory concentration (IC<sub>50</sub>) was defined as the concentration of drug that inhibited cell growth by

50% relative to untreated control. Cells did not reach plateau phase during the 48-h experiment period.

### Assessment of H<sub>2</sub>O<sub>2</sub> in HeLa-HyPer-Cyto cells

HyPer is the first fully genetically encoded fluorescent sensor capable of specifically detecting intracellular H<sub>2</sub>O<sub>2</sub>[35,36]. HeLa-HyPer-Cyto cells express HyPer protein in the cell cytoplasm. Cells at 80% confluence were exposed to AA (10 mM), GSH (640 µM), or the combination of AA and GSH. At 2 h of exposure, imaging for green fluorescence (500/528 nm) was performed with an Olympus IX71 fluorescence microscope and DP71 camera (Olympus, Center Valley, PA, USA). Fluorescence intensity was detected with a Synergy 2 fluorescence and luminescence plate reader (Biotek, Winooski, VT, USA) at excitation of 420 ± 9 or 500 ± 9 nm and emission of 500 ± 20 nm. The changes in HyPer fluorescence intensity at 500/520 relative to 420/520 were used to indicate changes in H<sub>2</sub>O<sub>2</sub> concentrations in the cells [35].

### Mouse tumor model and treatment procedures

The syngeneic murine pancreatic carcinoma PAN-02 cells (1 × 10<sup>6</sup>) suspended in normal saline solution were injected subcutaneously into the flank of female athymic mice (Ncr-nu/nu ages 5–8 weeks). When tumor volume reached ~30 to 40 mm<sup>3</sup>, the mice were randomly assigned to treatment groups: control group received daily saline solution osmotically equivalent to AA; ascorbate group received 4 g ascorbate/kg body wt daily; GSH group received 800 mg GSH/kg body wt daily. For combinations, AA was administered first, followed immediately by GSH. All drugs were administered by intraperitoneal injection. Longitudinal tumor volume was calculated from caliper measurements using volume = (length) × (width)<sup>2</sup> × 0.5. Body weight was measured on a digital pan balance. Treatment stopped at day 18, and the mice continued to be monitored until they reached preset criteria for euthanasia as described in a protocol approved by the Institutional Animal Care and Use Committee. Survival rate was recorded until day 30, when all mice were euthanized.

### Statistics

Mixed linear regression was used to compare group-specific tumor progress over time. Survival-rate comparison and single-point comparison between groups used paired *t* test. All statistic analysis was two-sided and assessed for significance at the 5% level.

## Results

### Usage of iv GSH and the concurrent usage of iv ascorbate by CAIM practitioners

As the usage of iv AA in CAIM has been published in detail [9], our focus for this survey was iv GSH use. One hundred sixty-nine survey forms were distributed to attendees at the CAIM conference in April 2011. Ninety-four forms were returned, a response rate of 55.6%. Of the respondents, 75.5% (71/94) had an MD degree, and others were

**Table 1**  
Number of survey respondents (CAIM practitioners) who use iv glutathione and concurrently use iv ascorbate.

Survey forms distributed	Respondents	Use iv AA	Use iv GSH	Use iv AA and iv GSH			
				Same patient	Same day	Same bag	
169	94 (55.6% response rate)	89 (85.4% concurrently use iv GSH)	85 (89.4% concurrently use iv AA)	76	65	13	t1.5

Survey forms were distributed to the attendees of a CAIM conference in April 2011. GSH, glutathione; AA, ascorbate; iv, intravenous.

t2.1 **Table 2**  
Dose and frequency of iv glutathione used by survey respondents.


t2.2		Mean	Median	Range
t2.3				
t2.4	Doses of GSH (mg/treatment)	1567	1750	300–4000
t2.5	Frequency (doses/week/respondent)	9.4	15.5	1–30

187 ND, DO, RN, MN, PA, and nurse practitioners. Eighty-nine respondents  
188 used iv AA, 85 used iv GSH. Of the 85 who used iv GSH, 76 (89.4%)  
189 coadministered iv AA and iv GSH to the same patient; 65 of them  
190 (76.5%) administered both drugs on the same day, and 13 of them  
191 (15.3%) mixed the two drugs into the same infusion bag (Table 1). The  
192 overall concurrent use of both iv ascorbate and iv GSH was 80.9%  
193 (76/94) in all respondents (Table 1). Furthermore, 85.4% (76/89)  
194 of the respondents who used iv AA coadministered iv GSH to the  
195 same patient (Table 1). With the large scale of iv AA usage by CAIM  
196 practitioners (exceeding 10,000 patients per year [9]), there is a  
197 compelling need to investigate potential drug–drug interactions  
198 between iv AA and iv GSH.

199 The total number of iv infusions of GSH given was estimated at  
200 808 infusions per week by the survey respondents, with a wide range of  
201 1–30 infusions per practitioner per week (Table 2). The dose of iv GSH  
202 per infusion ranged from 300 to >4000 mg, averaging 1567 mg/infusion  
203 (Table 2). Intravenous GSH was used for a variety of conditions, labeled  
204 as detoxification (82 respondents, 24.55% of total usage), neurologic  
205 disorders (74 respondents, 22.16%), neuropathy (64 respondents,  
206 19.16%), cancer (43 respondents, 12.87%), infections (36 respondents,  
207 10.78%), and other conditions (35 respondents, 10.48%) (Fig. 1).

#### 208 Sensitivity of various cancer cells to pharmacologic concentrations of 209 ascorbate

210 Studies have shown that AA in pharmacologic concentrations  
211 achievable with iv infusion can induce H<sub>2</sub>O<sub>2</sub>-dependent cell death  
212 in cancer cells [12–15,37–40]. We tested the cytotoxic effect of  
213 pharmacologic AA in 10 cancer cell lines. Tested cells were incu-




**Fig. 2.** Sensitivity of cancer cells to pharmacological concentrations of ascorbate. Human pancreatic cancer (MIA PaCa-2, HPAF-II, and PANC-1), lung cancer (A549), ovarian cancer (OvCar5), breast cancer (MCF-7), melanoma (B16), prostate cancer (PC-3), and cervical cancer (HeLa) cell lines and a mouse pancreatic cancer cell line (Pan-02) were exposed to serial dilutions (0–20 mM) of ascorbate. Cells were washed with PBS and viability was detected using MIT assay at 48 h of treatment. IC<sub>50</sub> was determined for the concentrations that reduced viability by 50% compared with matched untreated cells. All data represent two to four individual experiments, each done in triplicate (±SD).

214 bated with 0–20 mM AA, which is relevant to clinical concentrations  
215 achieved with iv AA. All tested cells were sensitive to AA treatment,  
216 although there were variations in their sensitivity (Fig. 2). AA  
217 concentrations causing a 50% decrease in cell survival (IC<sub>50</sub> values)  
218 ranged from 0.5 mM for MCF-7 (breast cancer) to 3 mM for B16  
219 (melanoma), concentrations easily achievable from iv infusion [10].


#### 220 Glutathione reduces the cytotoxicity of ascorbate toward cancer cells

221 Having established the dose response of ascorbate-induced  
222 cytotoxicity for each cell line, we added GSH cotreatment to the AA  
223 treatment. To determine the GSH dose, cells were incubated with a  
224 series of dilutions of GSH for 48 h (data not shown). A concentration  
225 relevant to clinical GSH use (640 μM) [26] provided 0–25% decrease in

Other uses described by respondents	Number of respondents
Autism	7
Chronic Fatigue syndrome	6
Fibromyalgia	3
Presbycusis	1
Dental amalgam removal	1
Autoimmune disease	1
Methylation/glucuronidation, sulfation issues	1
Malabsorption	1
Asthma	1
Chemical sensitivity	2
Cold	1
Surgey, Emergent situation	1
Vasculitis	1
Gut healing	1
Encephalopathy	1
Pain	1
Depression	1
Headache	1
Itching	1
Learning disability	1
Thyroid disorder	1



**Fig. 1.** Number of survey respondents (CAIM practitioners) who use intravenous glutathione for various conditions. The number in the parentheses is the number of practitioners who use iv GSH for the indicated condition. The percentage denotes the portion of usage for the indicated condition in all usages.




**Fig. 3.** Glutathione reduces the cytotoxicity of ascorbate toward cancer cells. Human pancreatic cancer (MIA PaCa-2, HPAF-II, and PANC-1), lung cancer (A549), ovarian cancer (OvCar5), breast cancer (MCF-7), melanoma (B16), prostate cancer (PC-3), and cervical cancer (HeLa) cell lines and a mouse pancreatic cancer cell line (Pan-02) were treated with ascorbate (AA) at various concentrations, with or without glutathione (GSH; 640  $\mu$ M). Cell viability was examined using MTT assay at 48 h of treatment. (A) Dose response of cancer cell viabilities to the treatments. Blue lines show AA treatment alone, red lines show AA + GSH. (B) Percentage of cell death in treated cancer cells relative to untreated cells. The concentrations of AA were 1 mM for MCF-7, PC-3, and MIA PaCa-2; 1.5 mM for HPAF-II and OVARC5; 2 mM for PANC-1, Pan-02, A549, and HeLa; and 4 mM for B16. GSH was 640  $\mu$ M for all cell lines. All data represent two to four individual experiments each done in triplicate ( $\pm$ SD).

cell viability, depending on the cell line tested (Fig. 3B). This clinically relevant GSH concentration was chosen to combine with AA. Cells were incubated with AA or with AA + GSH for 48 h and viability was assessed. Across the tested concentration range of AA, addition of GSH dramatically reduced AA-induced cytotoxicity compared with AA treatment alone (Figs. 3A and B). The dose-response curves of each tested cell line shifted toward much less or no response to AA treatment (Fig. 3A). When GSH was combined, an impairment in the sensitivity to pharmacologic ascorbate treatment occurred in all the cancer cells tested, regardless of cell type or sensitivity of the cells to either AA or GSH alone.

#### Glutathione inhibits pharmacologic ascorbate-induced $H_2O_2$ production

The mechanism of action of AA-induced cancer cell death is through  $H_2O_2$  formation as AA is oxidized (catalyzed by transition metals), with  $Asc^+$  serving as intermediary [12–15,37,38]:  $AscH +$

$O_2 \rightarrow Asc^+ + O_2^{\cdot-} \rightarrow DHA + H_2O_2$ . GSH is able to prevent ascorbate oxidation [30], or reduce  $H_2O_2$  directly [25–29], and thus decrease its concentration. The decrease in  $H_2O_2$  concentration could then result in attenuation of the ascorbate-induced cytotoxicity [13,37]. To assess  $H_2O_2$  production by pharmacologic AA with and without addition of GSH, we used a human cervical cancer cell line, HeLa-HyPer-Cyto, that expresses a transfected  $H_2O_2$  fluorescent sensor—HyPer protein—in its cytoplasm. HyPer has one fluorescence-emission peak at  $\sim$ 516 nm and two excitation peaks at  $\sim$ 420 and  $\sim$ 500 nm [35]. Upon  $H_2O_2$  exposure, HyPer changes fluorescence with a decrease at  $\sim$ 420/516 nm proportional to the increase at  $\sim$ 500/516 nm [35]. As shown in Fig. 4A, treatment with 2 mM  $H_2O_2$  enhanced the fluorescence of HyPer at 500/520 nm, which serves as a positive control. Glutathione alone decreased the endogenous fluorescence showing as relative fluorescence intensity in Figs. 4A and 3B, consistent with its role as a  $H_2O_2$  reducer. At 2 h of AA treatment, the green fluorescence of HyPer at 500/520 nm was greatly enhanced compared with untreated control




**Fig. 4.** Glutathione reduces H<sub>2</sub>O<sub>2</sub> production by pharmacological concentrations of ascorbate. HeLa-HyPer-Cyto cells at 80% confluence were treated with AA (10 mM), GSH (640 μM), or AA + GSH for 2 h. H<sub>2</sub>O<sub>2</sub> (2 mM) was added as a positive control. (A) Imaging of HyPer green fluorescence. (B) Relative fluorescence intensity indicates intracellular H<sub>2</sub>O<sub>2</sub> concentrations and was determined by the changes in HyPer fluorescence at excitation/emission of 500/520 nm relative to 420/520 nm. Data were normalized to untreated control cells and represent two individual experiments, each done in six repeats (±SD). \**P*<0.05.

(Figs. 4A and B), indicating an increase in H<sub>2</sub>O<sub>2</sub> concentration in the cells. By adding 640 μM glutathione to the ascorbate treatment, the fluorescence intensity was lowered and showed no difference compared to untreated control cells or cells treated with GSH alone (Figs. 4A and B). These experiments demonstrated that glutathione inhibited the expected AA-induced H<sub>2</sub>O<sub>2</sub> production.

#### Glutathione reduces the tumor-inhibitory effect of ascorbate in a mouse pancreatic cancer model

To validate the *in vitro* attenuation of cytotoxicity by GSH in AA-treated cancer cells, we tested the combination of GSH and AA treatment *in vivo*. A mouse syngeneic pancreatic cancer cell line, PAN-02, was used to form subcutaneous xenografts in nude mice. Treatment was given by daily ip injections of saline as a control, 4 g/kg AA, 800 mg/kg GSH, or the combination of AA and GSH. AA treatment alone inhibited the growth of this aggressive tumor by 42% compared with saline-treated control (Fig. 5A), consistent with published studies [12]. AA treatment also improved survival rate (Fig. 5B). GSH treatment alone did not exhibit any increase or decrease in tumor growth (Fig. 5A). The addition of GSH to AA treatment attenuated the effect of AA, resulting in identical tumor growth compared to saline-treated control (Fig. 5A). Interestingly, GSH treatment alone showed a benefit in improved survival rate, but the combination of GSH with AA did not provide further improvement in survival rate compared with either AA or GSH alone (Fig. 5B). Taken together, adding GSH treatment simultaneously to high-dose AA treatment offers no benefit over AA treatment alone, and it appears



**Fig. 5.** Glutathione reduces the tumor-inhibitory effect of ascorbate in a mouse pancreatic cancer model. Pan02 subcutaneous xenografts were treated with ip doses of ascorbate (AA) 4 g/kg/day, glutathione (GSH) 800 mg/kg/day, or the combination of AA and GSH (AA + GSH). Control mice were treated with saline osmotically equivalent to AA. Tumor volume was calculated from caliper measurements using the equation volume = (length × width × width)/2. Treatment stopped at day 18, and the mice were monitored until they reached the preset criteria for euthanasia. (A) Longitudinal tumor growth under each treatment. (B) Survival of mice with each treatment. \**P*<0.05, \*\*\**P*<0.005. Standard errors are shown.

that GSH antagonizes ascorbate-induced tumor growth inhibition when these two treatments are used together.

#### Discussion

High-dose iv and intramuscular vitamin C or AA has endured as a therapy for infectious disease and cancer since its introduction in the first half of the 20th century [1–8,41,42]. Because of negative reports regarding its utility in chronic disease [43–45], high-dose iv AA has largely been abandoned by conventional medicine and has become a therapy primarily practiced by CAIM practitioners [9,46]. However, recent *in vitro* and *in vivo* research findings support the use of high-dose iv AA in cancer treatment and provide a mechanism for neoplastic cytotoxicity [12–15,37–40]. Parenteral administration of high doses of AA generates ascorbate radical in the extracellular space, which in turn reacts with a transition metal to produce H<sub>2</sub>O<sub>2</sub>. It is H<sub>2</sub>O<sub>2</sub> that acts as the cytotoxic agent and, as such, high-dose AA is a prodrug for H<sub>2</sub>O<sub>2</sub> with apparent targeted neoplastic cytotoxicity. Our data in this study confirm the pro-oxidant anti-cancer effect of ascorbate using clinically relevant conditions, as the AA-induced cancer cell death was attenuated by concurrent administration of the antioxidant GSH.

Because the administration of iv AA has been out of the purview of conventional medical practice but in use in CAIM practices, it has only recently been found what the extent of use is [9]. Our survey data in this paper showed that iv GSH is often used concurrent with iv AA

and administered to cancer patients on the same day and even within the same infusion (Tables 1 and 2 and Fig. 1). However, there is no scientific evidence to support the combination and no information about efficacy or drug–drug interactions. This preliminary report indicates that there is antagonism between ascorbate and glutathione in treating cancer, and therefore iv AA and iv GSH should not be coadministered on the same day to cancer patients.

Whereas the cytotoxic effect of high-dose AA is confirmed again in our study, combining GSH with AA significantly reduced the cytotoxic effect of AA. This antagonism occurs by GSH interfering with AA-induced H<sub>2</sub>O<sub>2</sub> production (Fig. 4). GSH is a well-known H<sub>2</sub>O<sub>2</sub> scavenger that directly reduces H<sub>2</sub>O<sub>2</sub> to H<sub>2</sub>O [25–29]. In addition, by chelating the transition metal, GSH can prevent *trans*-metal interactions with ascorbate radical and thus reduce H<sub>2</sub>O<sub>2</sub> formation [30]. As H<sub>2</sub>O<sub>2</sub> formation is an essential mechanism of AA antineoplastic action, the combination of GSH counteracts this important catalysis.

Consistent with published studies [12,15], our *in vivo* data demonstrate the effects of AA single-drug treatment in inhibiting pancreatic cancer growth (Fig. 5A). Of concern, addition of GSH to AA completely attenuated the tumor-inhibitory effect of AA treatment. GSH also failed to provide any additional survival benefit compared to AA single-drug treatment. It is fair to conclude from these data that adding GSH concurrent with AA treatment has no benefit over AA treatment alone and results in a detrimental effect through drug–drug interaction, with inhibition of the expected H<sub>2</sub>O<sub>2</sub> formation by AA oxidation.

GSH plays a pivotal role in drug metabolism through Phase I and Phase II metabolizing systems, through which elimination of drugs and their metabolites is enhanced [47]. This is important for cell and tissue detoxification, but may also inactivate or eliminate effective drug components or drug metabolites. GSH can decrease neurotoxicity associated with platin-based chemotherapy, through removal of platinum from the dorsal root ganglia, and spares nerve damage [17–21]. Of note, no reduction in the chemotherapeutic effect was observed in clinical trials when iv GSH was added before platin-based chemotherapy administration [17–21]. This benefit, however, may not extend to other types of chemotherapy. In fact, many studies suggest that elevated glutathione or glutathione synthesis ability contributes to chemoresistance in cancer cells [31,48–53]. In multidrug-resistant neoplastic cells, the GSH/glutathione S-transferase level is elevated, making these cells less likely to generate the reactive oxygen species (ROS) that can tip the cells into apoptosis [53–55]. In this regard, classic alkylating drugs and platin-based chemotherapy are exempt because of their reliance on pathways for cytotoxicity other than ROS-related ones [53]. Therefore, narrow classes of cytotoxic drugs such as platin-based chemotherapy may allow for coadministration of GSH given the beneficial findings in clinical trials [18–20]. However, when ROS are critical for neoplastic cell death, GSH is predicted to interfere and should not be coadministered on the same day.

It may be wise to expand the use of GSH with other chemotherapeutic regimens but perhaps only on days apart from chemotherapy administration, so that the benefit of tissue protection could be achieved while diminishing the risk of potential interference in antineoplastic effects. The pharmacokinetic behavior of iv GSH and the combining drug should be considered when suggesting a reasonable time of administration.

In this report we have demonstrated the reduction of the chemotherapeutic effect of high-dose AA by coadministration of GSH in cultured cells and parenterally in animal models and would predict a similar effect in humans. It would be a wise first step to investigate the pharmacokinetics of AA and GSH coadministration in healthy humans with an assessment of production of ascorbate radical and H<sub>2</sub>O<sub>2</sub>. In this way drug–drug interactions can be assessed outside of the clinical setting.

Because GSH is important in drug metabolism, antioxidant defense, immunology, nutrient metabolism, and regulation of cellular events [29,56], GSH has a powerful role in cellular protection and is implicated in cancer prevention [31,57,58]. Interestingly, in our animal experiment, GSH treatment alone did extend survival despite having no effect on tumor growth. As such, GSH could provide a tool for clinical practice in settings in which protection from highly oxidative processes is needed or in situations in which drug metabolism may need supporting. However, in clinical settings in which treatments are dependent on ROS and free radicals, such as conventional chemotherapy, GSH effects are counterproductive. Furthermore it may be said that when GSH is used with AA and certain chemotherapeutic drugs, GSH acts as a double-edged sword. There are obvious benefits of GSH use in reducing oxidant damage to normal cells such as nervous tissue, but in the case of pharmacologic AA, there is a reduction in H<sub>2</sub>O<sub>2</sub> production when used concurrently, with potential for dampening down signals that trigger neoplastic cell death. At this juncture, it does not appear that high-dose iv GSH acts as a pro-oxidant in the manner that iv AA does, although further research is needed. Based on the reported findings, we advise iv AA and iv GSH should not be coadministered on the same day in the clinical setting of cancer treatment. Simply put, GSH is an antioxidant and pharmacologic iv AA is a pro-oxidant, and when used concurrently effects can be canceled.

## Acknowledgments

The research was supported by a grant from The Hilton Family Foundation. The Hilton Family Foundation had no input in the trial design, evaluation of data, or writing of the report.

## References

- Woodhouse, D. L. The action of ascorbic acid on tumour metabolism: a preliminary note on the effects observed following injections into mice with tar-induced neoplasms. *Biochem. J.* **28**:1974–1976; 1934.
- Jorissen, W. P.; Belinfante, A. H. The induced oxidation of lactic acid by ascorbic acid and the cancer problem. *Science* **79**:13; 1934.
- Cameron, E.; Campbell, A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. *Chem. Biol. Interact.* **9**:285–315; 1974.
- Cameron, E.; Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. *Proc. Natl. Acad. Sci. U. S. A.* **73**:3685–3689; 1976.
- Cameron, E.; Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. *Proc. Natl. Acad. Sci. U. S. A.* **75**:4538–4542; 1978.
- Drisko, J. A.; Chapman, J.; Hunter, V. J. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. *J. Am. Coll. Nutr.* **22**:118–123; 2003.
- Padayatty, S. J.; Riordan, H. D.; Hewitt, S. M.; Katz, A.; Hoffer, L. J.; Levine, M. Intravenously administered vitamin C as cancer therapy: three cases. *Can. Med. Assoc. J.* **174**:937–942; 2006.
- McCormick, W. Cancer: the preconditioning factor in pathogenesis; a new etiologic approach. *Arch. Pediatr.* **71**:313–322; 1954.
- Padayatty, S. J.; Sun, A. Y.; Chen, Q.; Espey, M. G.; Drisko, J.; Levine, M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. *PLoS One* **5**:e11414; 2010.
- Padayatty, S. J.; Sun, H.; Wang, Y.; Riordan, H. D.; Hewitt, S. M.; Katz, A.; Wesley, R. A.; Levine, M. Vitamin C pharmacokinetics: implications for oral and intravenous use. *Ann. Intern. Med.* **140**:533–537; 2004.
- Chen, Q.; Espey, M. G.; Sun, A. Y.; Lee, J. H.; Krishna, M. C.; Shacter, E.; Choyke, P. L.; Pooput, C.; Kirk, K. L.; Buettner, G. R.; Levine, M. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid *in vivo*. *Proc. Natl. Acad. Sci. U. S. A.* **104**:8749–8754; 2007.
- Chen, Q.; Espey, M. G.; Sun, A. Y.; Pooput, C.; Kirk, K. L.; Krishna, M. C.; Khosh, D. B.; Drisko, J.; Levine, M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. *Proc. Natl. Acad. Sci. U. S. A.* **105**:11105–11109; 2008.
- Verrax, J.; Calderon, P. B. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. *Free Radic. Biol. Med.* **47**:32–40; 2009.
- Pollard, H. B.; Levine, M. A.; Eidelman, O.; Pollard, M. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. *In Vivo* **24**:249–255; 2010.

- 444 [15] Du, J.; Martin, S. M.; Levine, M.; Wagner, B. A.; Buettner, G. R.; Wang, S. H.;  
445 Taghiyev, A. F.; Du, C.; Knudson, C. M.; Cullen, J. J. Mechanisms of ascorbate-  
446 induced cytotoxicity in pancreatic cancer. *Clin. Cancer Res.* **16**:509–520; 2010.
- 447 [16] Hoffer, L. J.; Levine, M.; Assouline, S.; Melnychuk, D.; Padayatty, S. J.; Rosadiuk, K.;  
448 Rousseau, C.; Robitaille, L.; Miller Jr., W. H. Phase I clinical trial of i.v. ascorbic acid  
449 in advanced malignancy. *Ann. Oncol.* **19**:1969–1974; 2008.
- 450 [17] Hamers, F. P.; Brakkee, J. H.; Cavalletti, E.; Tedeschi, M.; Marmonti, L.; Pezzoni, G.;  
451 Neijt, J. P.; Gispens, W. H. Reduced glutathione protects against cisplatin-induced  
452 neurotoxicity in rats. *Cancer Res.* **53**:544–549; 1993.
- 453 [18] Cascinu, S.; Cordella, L.; Del Ferro, E.; Fronzoni, M.; Catalano, G. Neuroprotective  
454 effect of reduced glutathione on cisplatin-based chemotherapy in advanced  
455 gastric cancer: a randomized double-blind placebo-controlled trial. *J. Clin. Oncol.*  
456 **13**:26–32; 1995.
- 457 [19] Cascinu, S.; Catalano, V.; Cordella, L.; Labianca, R.; Giordani, P.; Baldelli, A. M.;  
458 Beretta, G. D.; Ubiali, E.; Catalano, G. Neuroprotective effect of reduced glutathione  
459 on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized,  
460 double-blind, placebo-controlled trial. *J. Clin. Oncol.* **20**:3478–3483; 2002.
- 461 [20] Smyth, J. F.; Bowman, A.; Perren, T.; Wilkinson, P.; Prescott, R. J.; Quinn, K. J.;  
462 Tedeschi, M. Glutathione reduces the toxicity and improves quality of life of  
463 women diagnosed with ovarian cancer treated with cisplatin: results of a double-  
464 blind, randomised trial. *Ann. Oncol.* **8**:569–573; 1997.
- 465 [21] Bohm, S.; Oriana, S.; Spatti, G.; Di Re, F.; Breasciani, G.; Pirovano, C.; Grosso, I.;  
466 Martini, C.; Caraceni, A.; Pilotti, S.; Zunino, F. Dose intensification of platinum  
467 compounds with glutathione protection as induction chemotherapy for advanced  
468 ovarian carcinoma. *Oncology* **57**:115–120; 1999.
- 469 [22] Sechi, G.; Deledda, M. G.; Bua, G.; Satta, W. M.; Deiana, G. A.; Pes, G. M.; Rosati, G.  
470 Reduced intravenous glutathione in the treatment of early Parkinson's disease.  
471 *Prog. Neuropsychopharmacol. Biol. Psychiatry* **20**:1159–1170; 1996.
- 472 [23] Hauser, R. A.; Lyons, K. E.; McClain, T.; Carter, S.; Perlmutter, D. Randomized,  
473 double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.  
474 *Mov. Disord.* **24**:979–983; 2009.
- 475 [24] Gil, H. W.; Kang, E. J.; Lee, K. H.; Yang, J. O.; Lee, E. Y.; Hong, S. Y. Effect of  
476 glutathione on the cadmium chelation of EDTA in a patient with cadmium  
477 intoxication. *Hum. Exp. Toxicol.* **30**:79–83; 2010.
- 478 [25] Arrick, B. A.; Nathan, C. F. Glutathione metabolism as a determinant of therapeutic  
479 efficacy: a review. *Cancer Res.* **44**:4224–4232; 1984.
- 480 [26] Aebi, S.; Assereto, R.; Lauterburg, B. H. High-dose intravenous glutathione in man:  
481 pharmacokinetics and effects on cyst(e)ine in plasma and urine. *Eur. J. Clin. Invest.*  
482 **21**:103–110; 1991.
- 483 [27] Winterbourn, C. C.; Metodiewa, D. Reaction of superoxide with glutathione and  
484 other thiols. *Methods Enzymol.* **251**:81–86; 1995.
- 485 [28] Winterbourn, C. C.; Metodiewa, D. Reactivity of biologically important thiol  
486 compounds with superoxide and hydrogen peroxide. *Free Radic. Biol. Med.* **27**:  
487 322–328; 1999.
- 488 [29] Wu, G.; Fang, Y. Z.; Yang, S.; Lupton, J. R.; Turner, N. D. Glutathione metabolism  
489 and its implications for health. *J. Nutr.* **134**:489–492; 2004.
- 490 [30] Winkler, B. S.; Orsell, S. M.; Rex, T. S. The redox couple between glutathione and  
491 ascorbic acid: a chemical and physiological perspective. *Free Radic. Biol. Med.* **17**:  
492 333–349; 1994.
- 493 [31] Meister, A. Glutathione, ascorbate, and cellular protection. *Cancer Res.* **54**:  
494 1969s–1975s; 1994.
- 495 [32] Ehrhart, J.; Zeevalk, G. D. Cooperative interaction between ascorbate and  
496 glutathione during mitochondrial impairment in mesencephalic cultures.  
497 *J. Neurochem.* **86**:1487–1497; 2003.
- 498 [33] Park, J. G.; Kramer, B. S.; Steinberg, S. M.; Carmichael, J.; Collins, J. M.; Minna, J. D.;  
499 Gazdar, A. F. Chemosensitivity testing of human colorectal carcinoma cell lines  
500 using a tetrazolium-based colorimetric assay. *Cancer Res.* **47**:5875–5879; 1987.
- 501 [34] Carmichael, J.; DeGraff, W. G.; Gazdar, A. F.; Minna, J. D.; Mitchell, J. B. Evaluation  
502 of a tetrazolium-based semiautomated colorimetric assay: assessment of  
503 chemosensitivity testing. *Cancer Res.* **47**:936–942; 1987.
- 504 [35] Belousov, V. V.; Fradkov, A. F.; Lukyanov, K. A.; Staroverov, D. B.; Shakhbazov, K. S.;  
505 Tersikh, A. V.; Lukyanov, S. Genetically encoded fluorescent indicator for  
506 intracellular hydrogen peroxide. *Nat. Methods* **3**:281–286; 2006.
- 507 [36] Choi, H.; Kim, S.; Mukhopadhyay, P.; Cho, S.; Woo, J.; Storz, G.; Ryu, S. E. Structural  
508 basis of the redox switch in the OxyR transcription factor. *Cell* **105**:103–113; 2001.
- 509 [37] Chen, Q.; Espey, M. G.; Krishna, M. C.; Mitchell, J. B.; Corpe, C. P.; Buettner, G. R.;  
510 Shacter, E.; Levine, M. Pharmacologic ascorbic acid concentrations selectively kill  
511 cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. *Proc.*  
512 *Natl. Acad. Sci. U. S. A.* **102**:13604–13609; 2005.
- 513 [38] Takemura, Y.; Satoh, M.; Satoh, K.; Hamada, H.; Sekido, Y.; Kubota, S. High dose of  
514 ascorbic acid induces cell death in mesothelioma cells. *Biochem. Biophys. Res.*  
515 *Commun.* **394**:249–253; 2010.
- 516 [39] Deubzer, B.; Mayer, F.; Kuci, Z.; Niewisch, M.; Merkel, G.; Handgretinger, R.;  
517 Bruchelt, G. H<sub>2</sub>O<sub>2</sub>-mediated cytotoxicity of pharmacologic ascorbate concentra-  
518 tions to neuroblastoma cells: potential role of lactate and ferritin. *Cell. Physiol.*  
519 *Biochem.* **25**:767–774; 2010.
- 520 [40] Fromberg, A.; Gutsch, D.; Schulze, D.; Vollbracht, C.; Weiss, G.; Czubayko, F.;  
521 Aigner, A. Ascorbate exerts anti-proliferative effects through cell cycle inhibition  
522 and sensitizes tumor cells towards cytostatic drugs. *Cancer Chemother. Pharmacol.*  
523 **67**:1157–1166; 2010.
- 524 [41] Jungeblut, C. W. Inactivation of poliomyelitis virus in vitro by crystalline vitamin C  
525 (ascorbic acid). *J. Exp. Med.* **62**:517–521; 1935.
- 526 [42] Klenner, F. R. The treatment of poliomyelitis and other virus diseases with vitamin  
527 C. *South. Med. Surg.* **111**:209–214; 1949.
- 528 [43] Sabin, A. B.; Vitamin, C. in relation to experimental poliomyelitis : with incidental  
529 observations on certain manifestations in Macacus rhesus monkeys on a scorbutic  
530 diet. *J. Exp. Med.* **69**:507–516; 1939.
- 531 [44] Creagan, E. T.; Moertel, C. G.; O'Fallon, J. R.; Schutt, A. J.; O'Connell, M. J.; Rubin, J.;  
532 Frytak, S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients  
533 with advanced cancer: a controlled trial. *N. Engl. J. Med.* **301**:687–690; 1979.
- 534 [45] Moertel, C. G.; Fleming, T. R.; Creagan, E. T.; Rubin, J.; O'Connell, M. J.; Ames, M. M.  
535 High-dose vitamin C versus placebo in the treatment of patients with advanced  
536 cancer who have had no prior chemotherapy: a randomized double-blind  
537 comparison. *N. Engl. J. Med.* **312**:137–141; 1985.
- 538 [46] Gaby, A. R. Intravenous nutrient therapy: the "Myers' cocktail". *Altern. Med. Rev.* **7**:  
539 389–403; 2002.
- 540 [47] Hayes, A. W. Metabolism: a determinant of toxicity, In: Hayes, A.W. (Ed.),  
541 Principles and Methods of Toxicology, 5th edition. Informa Healthcare, New York,  
542 pp. 147–156; 2008.
- 543 [48] Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated  
544 mechanisms: a radical therapeutic approach? *Nat. Rev. Drug Discov.* **8**:579–591;  
545 2009.
- 546 [49] Ozols, R. F.; O'Dwyer, P. J.; Hamilton, T. C.; Young, R. C. The role of glutathione in  
547 drug resistance. *Cancer Treat. Rev.* **17** (Suppl. A):45–50; 1990.
- 548 [50] Lee, F. Y.; Siemann, D. W.; Sutherland, R. M. Changes in cellular glutathione  
549 content during adriamycin treatment in human ovarian cancer—a possible  
550 indicator of chemosensitivity. *Br. J. Cancer* **60**:291–298; 1989.
- 551 [51] Godwin, A. K.; Meister, A.; O'Dwyer, P. J.; Huang, C. S.; Hamilton, T. C.; Anderson,  
552 M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated  
553 with marked increase of glutathione synthesis. *Proc. Natl. Acad. Sci. U. S. A.* **89**:  
554 3070–3074; 1992.
- 555 [52] Ozols, R. F.; Hamilton, T. C.; Masuda, H.; Young, R. C. Manipulation of cellular thiols  
556 to influence drug resistance. In: Woolley, P.V., Tew, K.D. (Eds.), Bristol Myers  
557 Symposium. Mechanisms of Drug Resistance in Neoplastic Cells, vol. 9. Academic  
558 Press, New York, pp. 289–305; 1988.
- 559 [53] Tew, K. D. Glutathione-associated enzymes in anticancer drug resistance. *Cancer*  
560 *Res.* **54**:4313–4320; 1994.
- 561 [54] Hayes, J. D.; Pulford, D. J. The glutathione S-transferase supergene family:  
562 regulation of GST and the contribution of the isoenzymes to cancer chemoprotec-  
563 tion and drug resistance. *Crit. Rev. Biochem. Mol. Biol.* **30**:445–600; 1995.
- 564 [55] Lo, H. W.; Ali-Osman, F. Genetic polymorphism and function of glutathione  
565 S-transferases in tumor drug resistance. *Curr. Opin. Pharmacol.* **7**:367–374;  
566 2007.
- 567 [56] Droge, W.; Schulze-Osthoff, K.; Mihm, S.; Galter, D.; Schenk, H.; Eck, H. P.; Roth, S.;  
568 Gmunder, H. Functions of glutathione and glutathione disulfide in immunology  
569 and immunopathology. *FASEB J.* **8**:1131–1138; 1994.
- 570 [57] Jana, S.; Mandlekar, S. Role of phase II drug metabolizing enzymes in cancer  
571 chemoprevention. *Curr. Drug Metab.* **10**:595–616; 2009.
- 572 [58] Talalay, P.; Fahey, J. W.; Holtzclaw, W. D.; Prestera, T.; Zhang, Y. Chemoprotection  
573 against cancer by phase 2 enzyme induction. *Toxicol. Lett.* **82–83**:173–179; 1995.